IL1A and hepatocellular carcinoma: Our in vitro studies confirmed that IL‐1α/β treatment significantly reduces PGC‐1α and FXR‐α mRNA levels in the human hepatoma cell line HepG2, in human and mouse primary hepatocytes, as previously reported.62